ongoing

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

1 month ago

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression inTransthyretin (ATTR) Amyloidosis

Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time…

1 month ago

BioPorto Sponsors Exhibits to Showcase Launch of ProNephro AKI in the U.S. and Ongoing Marketing of The NGAL Test to Clinicians at Major Healthcare Conferences

November 08, 2024 11:03 ET | Source: BioPorto A/S 8 November 2024 New Release BioPorto Sponsors Exhibits to Showcase Launch…

1 month ago
Show previous Posts